CGC vs SNDL: How Canopy Growth Corporation and SNDL Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CGC and SNDL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CGC and SNDL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Canopy Growth Corporation is one of Canada's largest cannabis companies, based in Smiths Falls, Ontario. It sells recreational (adult-use) and medical cannabis in Canada, exports medical cannabis to international markets in Europe and Australia, and owns Storz & Bickel, a maker of premium vaporizer devices. Its revenue comes mainly from selling cannabis flower, pre-rolls, vapes, edibles, and beverages under brands like Tweed and Doja, plus device sales. In fiscal 2026 the company completed its acquisition of MTL Cannabis, a move it says makes it Canada's leading medical-cannabis provider by revenue, and reported that its core cannabis business returned to growth after years of contraction.

Full CGC guide

SNDL Inc. (Nasdaq: SNDL), headquartered in Calgary, Alberta, is one of the largest private-sector retailers of liquor and cannabis in Canada and also operates a cannabis production business and a portfolio of cannabis-related investments. The company reports through four segments: Liquor Retail (banners including Wine and Beyond, Liquor Depot, and Ace Liquor), Cannabis Retail (banners including Value Buds, Spiritleaf, and Cost Cannabis, spanning roughly 190 locations as of early 2026), Cannabis Operations (cultivation, manufacturing, and branded products sold across Canada and internationally), and Investments. This structure makes SNDL unusual in the cannabis space because a large share of its revenue comes from the relatively stable business of selling regulated alcohol, which cushions the more volatile cannabis segments.

Full SNDL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CGC drivers: Core cannabis business back to growth; MTL Cannabis and medical leadership.
• SNDL drivers: Retail Scale Across Liquor and Cannabis; Debt-Free Balance Sheet and Cash Position.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is that Canopy is still unprofitable in a brutally competitive industry. For SNDL, the dominant risk is profitability: despite roughly C$946 million of annual revenue, SNDL has struggled to produce consistent net income, reporting a net loss of about C$6 million for full-year 2025 and only break-even adjusted operating income, so margins remain thin and can turn negative.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CGC if you believe its drivers more; SNDL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CGC and SNDL guides.

CGC. These figures are qualitative and tied to the asOf date; verify live numbers before acting. Because Canopy is unprofitable, standard earnings multiples do not apply, and the stock trades on revenue trajectory, cash runway, and expectations for cannabis reform rather than on profits. Reported financials are also in Canadian dollars, so US-dollar figures depend on exchange rates. Treat any single quarter with caution: cannabis results swing on pricing, one-time charges, and restructuring.

SNDL. SNDL's valuation is unusual because much of its worth sits in cash and investments rather than in current earnings. With a net loss in 2025 and only break-even adjusted operating income, traditional price-to-earnings multiples are not meaningful, so investors often look instead at the company's revenue, its large debt-free cash balance, and the carrying value of its Investments segment relative to the market capitalization. Because the balance sheet holds a significant cash cushion against a market cap in the hundreds of millions, a notable portion of the equity value is effectively backed by cash and holdings, which is part of why some observers frame SNDL as an asset-and-optionality story rather than a conventional earnings multiple.

Headline figures (approximate, Jul 2026): CGC shows revenue trend (fy2026) Modest annual growth (roughly mid-single-digit percent), the first sustained return to growth after years of contraction, growth drivers Double-digit gains in Canadian adult-use, Canadian medical, and international cannabis; device sales (Storz & Bickel) were softer, profitability Still net-loss-making, but fiscal 2026 net loss from continuing operations narrowed roughly by half versus the prior year, balance sheet Shifted to a net-cash position after a January 2026 recapitalization, reducing near-term financing risk; SNDL shows net revenue (fy2025) ~C$946 million (up ~2.8% YoY), net revenue (q1 2026) ~C$196 million (down ~4.4% YoY), gross margin (fy2025) ~27.3% (record gross profit ~C$259 million), net income / loss (fy2025) Net loss of ~C$6 million; adjusted operating income ~break-even.

CGC and SNDL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CGC and SNDL exposure against your real portfolio. It is not an investment adviser.